Gene · 1633
Papers2,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy. | Pharmaceutics | 2024 | 38258105 | PubTator, text mining | PubMed |
| Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis. | Mult Scler Relat Disord | 2024 | 38181696 | PubTator, text mining | PubMed |
| Prediction of miRNA‑mRNA network regulating the migration ability of cytarabine‑resistant HL60 cells. | Biomed Rep | 2024 | 38170076 | PubTator, text mining | PubMed |
| RNA sequencing and proteomic profiling reveal alterations by MPTP in chronic stomach mucosal injury in tree shrew Chinese (Tupaia belangeri chinensis). | Sci Rep | 2024 | 38168759 | PubTator, text mining | PubMed |
Nicotine promotes epithelial to mesenchymal transition and gemcitabine resistance via hENT1/RRM1 signalling in pancreatic cancer and chemosensitizing effects of Embelin-a naturally occurring benzoquinone. | Sci Total Environ | 2024 | 38163613 | PubTator, text mining | PubMed |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | 38064712 | PubTator, text mining | PubMed |
| CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy. | Ann Hematol | 2024 | 37917373 | PubTator, text mining | PubMed |
| Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. | Blood Adv | 2024 | 37389830 | PubTator, text mining | PubMed |
| Harnessing filamentous phages for enhanced stroke recovery. | Front Immunol | 2023 | 38299142 | PubTator, text mining | PubMed |
| Impact of Disease-Modifying Therapies on Gut-Brain Axis in Multiple Sclerosis. | Medicina (Kaunas) | 2023 | 38276041 | PubTator, text mining | PubMed |
| The Functional Roles of MDSCs in Severe COVID-19 Pathogenesis. | Viruses | 2023 | 38257728 | PubTator, text mining | PubMed |
| Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance. | Int J Mol Sci | 2023 | 38203655 | PubTator, text mining | PubMed |
| Effect of Shading on Physiological Attributes and Proteomic Analysis of Tea during Low Temperatures. | Plants (Basel) | 2023 | 38202371 | PubTator, text mining | PubMed |
| Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications. | Front Pharmacol | 2023 | 38130408 | PubTator, text mining | PubMed |
| MicroRNA-451a inhibits gemcitabine-refractory biliary tract cancer progression by suppressing the MIF-mediated PI3K/AKT pathway. | Mol Ther Nucleic Acids | 2023 | 38111913 | PubTator, text mining | PubMed |
| Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms. | Chin Herb Med | 2023 | 38094015 | PubTator, text mining | PubMed |
| Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies. | Cell Rep Med | 2023 | 38086380 | PubTator, text mining | PubMed |
| Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response. | Ther Adv Neurol Disord | 2023 | 38084102 | PubTator, text mining | PubMed |
| Genome-wide CRISPR/Cas9 screening for drug resistance in tumors. | Front Pharmacol | 2023 | 38084101 | PubTator, text mining | PubMed |
| Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine? | Front Immunol | 2023 | 38077398 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1633/papers?page=4